On May 22, 2025, NeoGenomics, Inc. held its annual meeting where stockholders approved an amendment to its 2023 Equity Incentive Plan, increasing share issuance by 4.3 million shares and establishing a minimum one-year vesting period for awards. The meeting saw participation from approximately 87.99% of outstanding voting stock with all director nominations and proposals passing successfully.